Colorectal Cancer Treatment and Survival Outcomes

Colorectal cancer remains a leading cause of cancer mortality worldwide, yet advances in multimodal management have steadily improved patient survival. The cornerstone of curative therapy for localised disease is surgical resection of the primary tumour, often combined with perioperative chemotherapy and, in rectal cancer, radiotherapy. Adjuvant chemotherapy reduces risk of recurrence by targeting micrometastatic disease, while neoadjuvant approaches may downstage tumours and permit sphincter‐sparing techniques. In the metastatic setting, metastasectomy—particularly of liver lesions—has transformed prognoses for selected patients. Novel systemic agents, including targeted therapies and immunotherapies, have further extended survival in advanced disease. Despite these gains, outcomes vary by age, comorbidity burden, geographic region and tumour stage. Population‐based analyses reveal that older or frail patients often receive less aggressive treatment, contributing to marked differences in net survival. Efforts to refine risk stratification, optimise patient selection for surgery and integrate personalised systemic regimens remain central to reducing global disparities and improving long‐term disease control.

Research from Nature Portfolio

A large population‐based study examined the influence of comorbidity on colorectal cancer‐specific and non‐cancer mortality using comprehensive mortality modelling. Patients with higher comorbidity scores had substantially elevated risks of both cancer‐related and other‐cause death over ten years, underscoring the importance of competing risks in survival estimation. Variation between comorbidity indices was marginal, suggesting that routine assessment of pre‐existing conditions can inform prognosis and guide treatment intensity.

Colorectal Cancer Treatment and Survival Outcomes publication trend

The graph below shows the total number of articles in colorectal cancer treatment and survival outcomes across all publications each year (not limited to Nature Index journals).

Technical terms

Adjuvant therapy: Treatment given after primary surgery to eradicate residual microscopic disease.

Neoadjuvant therapy: Treatment administered before surgery to reduce tumour size or stage.

Metastasectomy: Surgical removal of distant metastatic lesions.

Disease‐free survival (DFS): Time from treatment to recurrence of cancer or death from any cause.

Overall survival (OS): Time from diagnosis or treatment initiation to death from any cause.

Comorbidity index: A weighted scoring system quantifying concurrent medical conditions to predict outcomes.

References

1. Age-related differences in staging, treatment and net survival in relation to frailty in adults with colon cancer in England: an analysis of the COloRECTal cancer data repository (CORECT-R) resource. Age and Ageing (2025).
2. Retroperitoneal Lymph Node Dissection in Colorectal Cancer with Lymph Node Metastasis: A Systematic Review. Cancers (2023).
3. Population-based SEER analysis of survival in colorectal cancer patients with or without resection of lung and liver metastases. BMC Cancer (2020).
4. Disease recurrence after colorectal cancer surgery in the modern era: a population-based study. International Journal of Colorectal Disease (2021).
5. The effects of comorbidity on colorectal cancer mortality in an Australian cancer population. Scientific Reports (2019).